Running a feedback pass on the newsletter this week. If something's resonating, tell me. If something's missing, tell me that too. Drop me a quick note. Short answers are the most useful ones.

✦ Check out this Week's Partner: Ghost

Neurotechnology News | April 25 – May 1, 2026

Let's cut through the noise.

This week, the Food and Drug Administration (FDA) cleared Motif Neurotech's depression implant for human trials, and a pediatric autism study reported positive accelerated transcranial magnetic stimulation (TMS) results. ResMed's $340M Noctrix acquisition and Axoft's $55M round signaled that capital is pricing semi-invasive neurotech as integrable infrastructure. Meanwhile, Vermont advanced state neurorights legislation as a Neurology paper called consumer neural-data protections inadequate. Bottom line: the field is optimizing for deployment, and governance is starting to notice.

⚡ Signal of the Week

On April 27, the FDA granted Motif Neurotech an Investigational Device Exemption (IDE) for RESONATE, the first human trial of its skull-mounted, wirelessly-powered microstimulator for treatment-resistant depression (TRD). The implant sits epidurally inside the bone, with no battery, no leads, and no brain penetration, enabling a roughly 20-minute outpatient procedure. This stands above the rest because the FDA cleared a novel device geometry rather than a 510(k) predicate, validating a third architectural class between non-invasive TMS and intracortical deep brain stimulation (DBS). If RESONATE shows efficacy, the per-patient economics of psychiatric neuromodulation get rewritten, and home-use stimulation for mental illness moves from concept to category. The clinical question is efficacy; the harder question is what psychiatric care becomes when implanted stimulation is a 20-minute outpatient option.

Published: April 29, 2026
Read more
➡ Five-day course of magnetic brain stimulation could help autistic children
➡ Accelerated continuous theta burst stimulation targeting left primary motor cortex for children with autism spectrum disorder

A multicenter sham-controlled trial tested five-day accelerated continuous theta-burst stimulation (cTBS) targeting left primary motor cortex in autistic children. Social communication improved at one-month follow-up with a favorable short-term safety profile.

💡 Big Picture: Compressing weeks-long protocols into five days addresses the throughput bottleneck that keeps neuromodulation locked inside specialist centers.

Published: April 27, 2026
Read more
➡️ A Brain Implant for Depression Is About to Be Tested in Humans
➡ Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI for Treatment-Resistant Depression

The FDA granted Motif Neurotech an IDE for the RESONATE early feasibility study of its XCS System. The XCS is an epidural skull-mounted wirelessly powered microstimulator for TRD, slated for trials at eight US medical centers in adults who have failed two or more medications.

💡 Big Picture: First IDE for a non-penetrating, battery-less, lead-less psychiatric implant validates a third architectural class between TMS and DBS.

Published: April 30, 2026
Read more
➡️ SetPoint to evaluate neuromod for multiple sclerosis
➡ SetPoint Medical Announces First Patients Enrolled in Pilot Study Evaluating Neuroimmune Modulation for Multiple Sclerosis

SetPoint enrolled the first patients in a 60-patient, 2:1 randomized, sham-controlled, double-blind multicenter pilot of its implanted vagus-nerve stimulator for relapsing-remitting multiple sclerosis (MS). The device delivers 60 seconds of stimulation per day, targeting remyelination as adjunct to standard disease-modifying therapy.

💡 Big Picture: Tests whether a peripheral nerve becomes a programmable input to the immune system, with minimum-viable implant complexity.

Published: April 29, 2026
Read more
➡️ Stabilizing brain-computer interfaces through alignment of latent dynamics

Karpowicz and colleagues introduced NoMAD (Nonlinear Manifold Alignment with Dynamics), an unsupervised algorithm using recurrent neural-network models to maintain BCI decoder stability without supervised recalibration. Validated offline on monkey M1 datasets across at least three months.

💡 Big Picture: Attacks decoder drift at the algorithm layer rather than the electrode, removing the largest operational tax on chronic BCI use.

Published: April 30, 2026
Read more
➡️ Snoring leader buys restless leg syndrome device maker
➡ ResMed Q3 FY26 Earnings Transcript

ResMed announced an acquisition of Noctrix Health for approximately $340 million, with close expected June 1, 2026. Noctrix's lead asset is Nidra, a non-drug wearable peripheral nerve stimulation therapy for medication-refractory restless legs syndrome.

💡 Big Picture: Incumbent acquisition validates that home-use peripheral neurostimulation now fits existing reimbursement, fulfillment, and patient-support infrastructure.

Published: April 29, 2026
Read more
➡️ US Brain Implant Company Tests With Patients in China
➡ Axoft Secures $55M Series A to Advance Clinical Trials Globally for its Bio-Inspired, Implantable Brain-Computer Interface

Axoft closed a $55 million Series A led by C.P. Group Innovation, funding a Boston GMP facility, expanded global trials, and US regulatory work. Its Fleuron probes, claimed roughly 10,000× softer than polyimide, have been implanted in 11 patients including one in Shanghai.

💡 Big Picture: Capacity-before-IDE sequencing argues that supply-chain readiness, not regulatory clearance, is the next binding constraint on next-gen BCI commercialization.

Published: April 27, 2026
Read more
➡️ Nervonik closes $52.5M Series B for peripheral nerve stim tech
➡ Nervonik Announces $52.5 Million Series B Financing to Advance Peripheral Nerve Stimulation Therapy

Los Angeles-based Nervonik raised $52.5 million led by Amzak Health for a peripheral nerve stimulator with closed-loop sensing. The lead records evoked compound action potentials (ECAPs) and stimulates simultaneously, enabling automatic real-time titration for chronic pain.

💡 Big Picture: Closed-loop sensing and stimulation on a single lead becomes table stakes; open-loop set-and-forget peripheral stim is increasingly obsolete.

Published: April 28, 2026
Read more
➡️ Get Ready for More Brain-Scanning Consumer Gadgets
➡ Neurable Open for Business: Scaling Neurotechnology Adoption Through Global OEM Integration

Neurable announced a shift from selling branded electroencephalography (EEG) headphones to licensing its sensors and signal-processing stack as embeddable components for third-party consumer hardware. The company will offer integration kits to original-equipment manufacturers (OEMs) across headphones, gaming gear, and wearables.

💡 Big Picture: Reframes consumer EEG as middleware infrastructure, but distributes accountability for consent and data handling across vendor, OEM, app, and cloud layers.

Published: May 1, 2026
Read more
➡️ AI Legislative Update: April 3, 2026
➡ VT H0814 Status Update

Vermont H.814, an act on neurological rights and artificial intelligence (AI) in health and human services, received a favorable report from the House Committee on Appropriations on May 1. The bill was previously engrossed on March 18, 2026, tracking the Colorado, California, and Montana neural-data privacy template.

💡 Big Picture: A fourth state-level neurorights regime forces multistate companies into per-jurisdiction consent and data-handling logic baked into product code.

Published: April 30, 2026
Read more
➡️ BCI startup Neurable looks to license its 'mind-reading' tech for consumer wearables
➡ Safeguarding Neural Data

A policy article in Neurology argued that neural-data protections remain underdeveloped as both clinical and consumer neurotechnologies expand distribution. The piece appeared the same week Neurable announced an OEM-licensing model that distributes EEG inference across third-party consumer hardware.

💡 Big Picture: Brain-data handling is now a supply-chain problem, where governance quality depends as much on contractual interfaces as on statute.

The week's news pulls in two directions at once. Motif's epidural microstimulator, SetPoint's vagus-nerve implant, and Neurable's licensing pivot all argue that lower procedural burden and broader distribution are how neurotech finally scales. The harder question is what minimum biological intimacy a therapy actually needs to remain clinically meaningful. And once a device is cleared for one indication and physically capable of many more, who polices the gap between cleared use and the technology's actual reach?

You prompt. The agent builds. Then it asks for a database.

Ghost is postgres made for this. Spin one up in seconds. Fork it like a branch. Delete it when you're done. Pay nothing when it's idle.

Your agent gets full sql, mcp support, as many databases. No dashboards. No provisioning. No forgotten dev databases draining your card at month end.

Build a weekend app. Fork the schema three different ways. Throw two of them out. Ghost doesn't care. The next prompt can spin up a fresh one.

You're already vibe-coding the app. Stop wiring up the backend.

Unlimited databases. Unlimited forms. 100 compute/hrs a month. 1tb of storage. Free.

Download Ghost